Literatur
- 1
Angus D, Linde-Zwirble W T, Clermonte G, Carcillo J, Pinsky M R.
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome,
and associated costs of care.
Crit Care Med.
2001;
29
1303-1310
- 2
Bernard G R, Vincent J L, Laterre P F. et al .
Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med.
2001;
344
699-709
- 3
Boerma E C, Mathura K R, van der Voort P. et al .
Quantifying bedside-derived imaging of microcirculatory abnormalities in septic patients.
Crit. Care.
2005;
9
R601-R606
- 4
de Backer D, Creteur J, Dubois M. et al .
Microvascular alterations in patients with acute severe heart failure and cardiogenic
shock.
Am Heart J.
2004;
147
91-99
- 5
de Backer D, Creteur J, Preiser J C, Dubois M J, Vincent J L.
Microvascular blood flow is altered in patients with sepsis.
Am J Respir Crit Care Med.
2002;
166
98-104
- 6
de Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent J L.
Effects of drotrecogin alfa activated on microcirculatory alterations in patients
with severe sepsis.
Crit Care Med.
2006;
34
1918-1924
- 7
Dhainaut J -F, Yan S B, Margolt B D, Lorente J A, Russell J M. et al .
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host
coagulatory response in patients with severe sepsis.
Thromb Haemost.
2003;
90
642-650
- 8
Granger D N, Kubes P.
The microcirculation and inflammation: modulation of leukocyte-endothelial cell interaction.
J Leukoc Biol.
1994;
55
662-675
- 9
Groner W, Winkelman J W, Harris A G, Ince C, Bouma G J, Messmer K. et al .
Orthogonal polarization spectral imaging.
Nature Med.
1999;
3
1209-1213
- 10
Hoffmann J N.
Therapeutische Optionen zur Verbesserung der Mikrozirkulation.
J Anästhesie Intensivbehandlung.
2004;
121-122
- 11
Hoffmann J N, Vollmar B, Laschke M, Inthorn D, Fertmann J, Schildberg F W. et al .
Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.
Crit Care Med.
2004;
32
1011-1017
- 12
Hoffmann J N, Vollmar B, Laschke M, Inthorn D, Kaneider N, Dunzendoerfer S. et al
.
Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic
and cellular mechanisms.
Thromb Haemost.
2002;
88
242-252
- 13
Hoffmann J N, Wiedermann C J, Juers M. et al .
Benefit/riskprofile of high-dose antithrombin in patients with severe sepsis treated
with and without concomitant heparin.
Thromb Haemost.
2006;
95
850-856
- 14
Iba T, Kidokoro A, Fukunaga M.
Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial
interaction in a rat lipopolysaccharide model.
Crit Care Med.
2005;
33
368-372
- 15
Ince C.
The microcirculation is the motor of sepsis.
Critical Care.
2005;
9
S13-S19
- 16
LeDoux D, Astiz M E, Carpati C M, Rackow E C.
Effects of perfusion pressure on tissue perfusion in septic shock.
Crit Care Med.
2000;
28
2729-2733
- 17
Rivers E, Nguyen B, Havstad S. et al .
Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med.
2001;
345
1368-1377
- 18
Sakr Y, Dubois M, de Backer D. et al .
Persistent microcirculatory alterations are associated with organ failure and death
in patients with septic shock.
Crit Care Med.
2004;
32
1825-1831
- 19
Vincent J L.
Plugging the leaks? New insights into synthetic colloids.
Crit Care Med.
1991;
19
316-318
- 20
White B, Schmidt M, Murphy C. et al .
Activated protein C inhibits lipopolysaccharide induced nuclear translocation of nuclear
factor kB (NF-kB) and tumor necrosis factor (TNF-alpha) production in the THP-1 monocytic
cell line.
Br J Haematol.
2000;
110
130-134
Priv.-Doz. Dr. J. N. Hoffmann
Oberarzt, Chirurgische Klinik und Poliklinik - Großhadern, Universität München
Marchioninistraße 15
81377 München
Phone: 089/70950
Fax: 089/70955706
Email: Johannes.Hoffmann@med.uni-muenchen.de
